Leading the Way in Life Science Technologies

GEN Exclusives

More »

Market and Technology Analysis

More »

For full access to this article login to GEN Select now.

Jul 16, 2014

Personalized Medicine Market Trends, Part I

This first of two back-to-back GEN reports tells you what's trending in this expanding space.

Personalized Medicine Market Trends, Part I

Whereas cancer was for many years the singular driver of personalized medicine, other areas are making inroads into this space. [Duke Center for Personalized and Precision Medicine]

  • This GEN Market & Tech Analysis report is the first of two reports designed to frame some of the market trends operative in the ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.
    •  


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »